METHOD OF TREATING PATIENTS WITH HEPATORENAL SYNDROME TYPE 1

    公开(公告)号:US20200237856A1

    公开(公告)日:2020-07-30

    申请号:US16828681

    申请日:2020-03-24

    摘要: The principles and embodiments of the present disclosure relate to methods for using terlipressin to treat a patient having impaired renal function associated with liver disease. A method of treating an adult patient with type 1 hepatorenal syndrome (HRS-1) may include assessing a baseline serum creatinine level prior to administration of terlipressin to the patient, initiating dosing of about 0.5 mg to about 1 mg of terlipressin to the patient every 6 hours by IV for 1-3 days, assessing a serum creatinine level in the patient at day 4±1 day from initiating dosing, administering a modified dosage of terlipressin based on a comparison of the assessed serum creatinine level at day 4±1 day and the baseline serum creatinine level, and continuing administration until 24 hours after two consecutive serum creatinine levels of ≤1.5 mg/dL at least 2 hours apart for a maximum of 14 days. The treatment may result in verified reversal of the HRS-1.